NYSE
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Medical device outsource manufacturer offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.2B | $1.3B | $1.6B | $1.7B | $1.9B |
| Gross profit | $285.7M | $337.0M | $345.8M | $409.9M | $459.0M | $500.4M |
| Operating income | $120.6M | $135.7M | $112.7M | $163.3M | $208.2M | $221.3M |
| Net income | $77.3M | $96.8M | $66.4M | $90.7M | $119.9M | $102.8M |
| Diluted EPS | $2.33 | $2.91 | $1.99 | $2.69 | $3.36 | $2.89 |
| Operating cash flow | $181.3M | $156.7M | $116.4M | $180.2M | $205.2M | $196.1M |
| Free cash flow | $134.5M | $103.2M | $41.7M | $60.3M | $99.8M | $105.1M |
| Gross margin | 26.6% | 27.6% | 26.0% | 26.3% | 26.7% | 27.0% |
| Operating margin | 11.2% | 11.1% | 8.5% | 10.5% | 12.1% | 11.9% |
| Net margin | 7.2% | 7.9% | 5.0% | 5.8% | 7.0% | 5.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $427.9M | $431.4M | $449.5M | $437.4M | $476.5M | $467.7M | $472.1M | $439.6M |
| Gross profit | $117.4M | $116.6M | $116.8M | $120.3M | $129.2M | $126.2M | $124.8M | $109.6M |
| Operating income | $54.5M | $58.0M | $57.0M | $49.6M | $59.3M | $56.4M | $55.9M | $31.9M |
| Net income | $31.2M | $35.4M | $32.7M | -$22.5M | $37.0M | $39.7M | $48.6M | $16.5M |
| Diluted EPS | $0.88 | $0.99 | $0.90 | -$0.66 | $1.04 | $1.11 | $1.40 | $0.48 |
| Operating cash flow | $47.2M | $71.5M | $63.2M | $31.3M | $43.9M | $65.6M | $55.4M | $24.7M |
| Free cash flow | $16.1M | $45.5M | $44.1M | $6.1M | $24.9M | $46.3M | $27.9M | $737,000.00 |
| Gross margin | 27.4% | 27.0% | 26.0% | 27.5% | 27.1% | 27.0% | 26.4% | 24.9% |
| Operating margin | 12.7% | 13.4% | 12.7% | 11.3% | 12.5% | 12.1% | 11.8% | 7.2% |
| Net margin | 7.3% | 8.2% | 7.3% | -5.1% | 7.8% | 8.5% | 10.3% | 3.8% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Thor Kirk K· Chief Human Resources Officer | Tax withholding | 2,409 | $93.45 | $225,121.05 | filing |
| 2026-06-30 | Thor Kirk K· Chief Human Resources Officer | Option exercise | 6,120 | — | — | filing |
| 2026-05-20 | COYLE MICHAEL J | Award | 1,967 | $0.00 | $0.00 | filing |
| 2026-05-20 | Kapito Aaron | Award | 1,967 | $0.00 | $0.00 | filing |
| 2026-05-20 | Jeffers Alvin Tyrone | Award | 1,967 | $0.00 | $0.00 | filing |
| 2026-05-20 | Antrum Sheila | Award | 1,967 | $0.00 | $0.00 | filing |
| 2026-05-20 | Flanagan James Francis | Award | 1,967 | $0.00 | $0.00 | filing |
| 2026-05-20 | PASSERINI FILIPPO | Award | 1,967 | $0.00 | $0.00 | filing |
| 2026-05-20 | Capps Cheryl C | Award | 1,967 | $0.00 | $0.00 | filing |
| 2026-05-20 | MAXWELL MARTIN C | Award | 1,967 | $0.00 | $0.00 | filing |
| 2026-05-15 | Stephens Jim· President, CRM & Neuro | Tax withholding | 479 | $88.16 | $42,228.64 | filing |
| 2026-05-15 | Stephens Jim· President, CRM & Neuro | Option exercise | 491 | $0.00 | $0.00 | filing |
| 2026-05-15 | Stephens Jim· President, CRM & Neuro | Option exercise | 1,472 | $0.00 | $0.00 | filing |
| 2026-05-08 | Smith Diron· EVP, Chief Financial Officer | Tax withholding | 503 | $88.12 | $44,324.36 | filing |
| 2026-05-08 | Smith Diron· EVP, Chief Financial Officer | Option exercise | 2,063 | $0.00 | $0.00 | filing |
| 2026-03-31 | Harris John A· EVP, Global Ops and Manufactur | Tax withholding | 1,842 | $88.00 | $162,096.00 | filing |
| 2026-03-31 | Harris John A· EVP, Global Ops and Manufactur | Option exercise | 3,837 | — | — | filing |
| 2026-03-24 | Blackwood Lindsay K.· SVP, Gen Counsel & Secretary | Tax withholding | 1,049 | $86.19 | $90,413.31 | filing |
| 2026-03-24 | Carr Terence· EVP, Qlty & Regulatory Affairs | Tax withholding | 398 | $86.19 | $34,303.62 | filing |
| 2026-03-24 | Blackwood Lindsay K.· SVP, Gen Counsel & Secretary | Option exercise | 1,777 | — | — | filing |
| 2026-03-24 | Blackwood Lindsay K.· SVP, Gen Counsel & Secretary | Option exercise | 1,706 | — | — | filing |
| 2026-03-24 | Carr Terence· EVP, Qlty & Regulatory Affairs | Option exercise | 1,350 | — | — | filing |
| 2026-03-13 | Thomas Tommy P· VP, Corporate Controller | Sale | 825 | $85.00 | $70,125.00 | filing |
| 2026-03-12 | Kapito Aaron | Award | 410 | $0.00 | $0.00 | filing |
| 2026-03-12 | Flanagan James Francis | Award | 410 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.